Changed epitopes drive the antigenic drift for influenza A (H3N2) viruses

被引:30
作者
Huang, Jhang-Wei [1 ]
Yang, Jinn-Moon [1 ,2 ,3 ]
机构
[1] Natl Chiao Tung Univ, Inst Bioinformat & Syst Biol, Hsinchu 30050, Taiwan
[2] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu 30050, Taiwan
[3] Natl Chiao Tung Univ, Core Facil Struct Bioinformat, Hsinchu 30050, Taiwan
关键词
NEUTRALIZING ANTIBODY; HEMAGGLUTININ; EVOLUTION; SELECTION; BINDING;
D O I
10.1186/1471-2105-12-S1-S31
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: In circulating influenza viruses, gradually accumulated mutations on the glycoprotein hemagglutinin (HA), which interacts with infectivity-neutralizing antibodies, lead to the escape of immune system (called antigenic drift). The antibody recognition is highly correlated to the conformation change on the antigenic sites (epitopes), which locate on HA surface. To quantify a changed epitope for escaping from neutralizing antibodies is the basis for the antigenic drift and vaccine development. Results: We have developed an epitope-based method to identify the antigenic drift of influenza A utilizing the conformation changes on epitopes. A changed epitope, an antigenic site on HA with an accumulated conformation change to escape from neutralizing antibody, can be considered as a "key feature" for representing the antigenic drift. According to hemagglutination inhibition (HI) assays and HA/antibody complex structures, we statistically measured the conformation change of an epitope by considering the number of critical position mutations with high genetic diversity and antigenic scores. Experimental results show that two critical position mutations can induce the conformation change of an epitope to escape from the antibody recognition. Among five epitopes of HA, epitopes A and B, which are near to the receptor binding site, play a key role for neutralizing antibodies. In addition, two changed epitopes often drive the antigenic drift and can explain the selections of 24 WHO vaccine strains. Conclusions: Our method is able to quantify the changed epitopes on HA for predicting the antigenic variants and providing biological insights to the vaccine updates. We believe that our method is robust and useful for studying influenza virus evolution and vaccine development.
引用
收藏
页数:10
相关论文
共 22 条
[1]   The influenza virus resource at the national center for biotechnology information [J].
Bao, Yiming ;
Bolotov, Pavel ;
Dernovoy, Dmitry ;
Kiryutin, Boris ;
Zaslavsky, Leonid ;
Tatusova, Tatiana ;
Ostell, Jim ;
Lipman, David .
JOURNAL OF VIROLOGY, 2008, 82 (02) :596-601
[2]   An antibody that prevents the hemagglutinin low pH fusogenic transition [J].
Barbey-Martin, C ;
Gigant, B ;
Bizebard, T ;
Calder, LJ ;
Wharton, SA ;
Skehel, JJ ;
Knossow, M .
VIROLOGY, 2002, 294 (01) :70-74
[3]   STRUCTURE OF INFLUENZA-VIRUS HEMAGGLUTININ COMPLEXED WITH A NEUTRALIZING ANTIBODY [J].
BIZEBARD, T ;
GIGANT, B ;
RIGOLET, P ;
RASMUSSEN, B ;
DIAT, O ;
BOSECKE, P ;
WHARTON, SA ;
SKEHEL, JJ ;
KNOSSOW, M .
NATURE, 1995, 376 (6535) :92-94
[4]   ANTIGENIC DRIFT IN INFLUENZA VIRUS-H3 HEMAGGLUTININ FROM 1968 TO 1980 - MULTIPLE EVOLUTIONARY PATHWAYS AND SEQUENTIAL AMINO-ACID CHANGES AT KEY ANTIGENIC SITES [J].
BOTH, GW ;
SLEIGH, MJ ;
COX, NJ ;
KENDAL, AP .
JOURNAL OF VIROLOGY, 1983, 48 (01) :52-60
[5]   Predicting the evolution of human influenza A [J].
Bush, RM ;
Bender, CA ;
Subbarao, K ;
Cox, NJ ;
Fitch, WM .
SCIENCE, 1999, 286 (5446) :1921-1925
[6]  
*CDCP, 2007, INF VACC REL BIOL PR, P28
[7]   Rapid molecular analysis of the haemagglutinin gene of human influenza A H3N2 viruses isolated in Spain from 1996 to 2000 [J].
Coiras, MT ;
Aguilar, JC ;
Galiano, M ;
Carlos, S ;
Gregory, V ;
Lin, YP ;
Hay, A ;
Pérez-Breña, P .
ARCHIVES OF VIROLOGY, 2001, 146 (11) :2133-2147
[8]   GENETIC AND ANTIGENIC VARIATION IN THE HEMAGGLUTININ OF RECENTLY CIRCULATING HUMAN INFLUENZA-A (H3N2) VIRUSES IN THE UNITED-KINGDOM [J].
ELLIS, JS ;
CHAKRAVERTY, P ;
CLEWLEY, JP .
ARCHIVES OF VIROLOGY, 1995, 140 (11) :1889-1904
[9]   A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site [J].
Fleury, D ;
Barrère, B ;
Bizebard, T ;
Daniels, RS ;
Skehel, JJ ;
Knossow, M .
NATURE STRUCTURAL BIOLOGY, 1999, 6 (06) :530-534
[10]   Quantifying influenza vaccine efficacy and antigenic distance [J].
Gupta, Vishal ;
Earl, David J. ;
Deem, Michael W. .
VACCINE, 2006, 24 (18) :3881-3888